Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 19.5 | 17.2 | 17.8 | 18.2 | 18.0 | 17.8 | 17.7 | 17.9 |
| Operating profit | €bn | 1.65 | 1.80 | ||||||
| Net profit | €bn | 1.19 | 3.32 | -1.61 | -0.47 | -0.70 | 0.90 | 1.11 | 1.54 |
| EPS reported | € | 0.93 | 1.16 | ||||||
| Operating cashflow per share | € | 1.24 | 2.39 | ||||||
| Capex per share | € | 0.28 | 0.40 | ||||||
| FCF per share | € | 0.95 | 1.99 | ||||||
| Free cash flow | €bn | 0.90 | 1.90 | ||||||
| Net debt | €bn | 5.29 | 5.68 | ||||||
| Book value equity | €bn | 11.0 | 11.4 | ||||||
| Book value per share | € | 11.38 | 11.82 | ||||||
| Number of shares | m | 962.5 | 968.57 | ||||||
| DPS (TTM paid) | € | 0.85 | 0.85 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 24.99 | 18.52 | ||||||
| P/B LTM | x | 2.01 | 1.82 | ||||||
| P/S LTM | x | 1.24 | 1.18 | ||||||
| P/FCF LTM | x | 24.40 | 10.94 | ||||||
| EV/EBITDA LTM | x | 9.86 | 8.66 | ||||||
| EV/Sales LTM | x | 1.53 | 1.50 | ||||||
| Earnings Yield LTM | % | 4.00% | 5.40% | ||||||
| FCF Yield | % | 4.10% | 9.14% | ||||||
| Quality | |||||||||
| ROE | % | 8.18% | 10.05% | ||||||
| ROIC | % | 6.10% | 6.63% | ||||||
| Operating margin | % | 9.24% | 10.17% | ||||||
| Gross margin | % | 45.18% | 45.93% | ||||||
| FCF/Sales | % | 5.06% | 10.76% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +578.36% | ||||||
| Sales Growth YoY | % | -1.04% | -1.08% | ||||||
| Net Income Growth YoY | % | - | +587.65% | ||||||
| FCF Growth | % | +1.12% | +581.36% | ||||||
| Operating Profit Growth | % | +211.53% | +64.62% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.49% | 3.96% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 36.64% | 31.57% | ||||||
| FCF/Debt | x | 0.11 | 0.25 | ||||||
| Net Debt/EBITDA | x | 1.91 | 1.86 | ||||||
| EBIT/Net interest | x | 4.76 | 5.22 | ||||||
| Net debt/market cap | % | 24.01% | 27.30% | ||||||
| Net debt/Equity | x | 0.48 | 0.50 | ||||||
| Gross debt/equity | x | 0.74 | 0.65 | ||||||
ETFs that hold Koninklijke Philips
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Ossiam EUROPE ESG MACHINE LEARNING | OSX4.DE | 10 | 2.12% |
Funds with Koninklijke Philips among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Koninklijke Philips N.V. operates as a leading global healthcare technology enterprise with a presence across North America and numerous international markets. Its operations are organized into three primary divisions: Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses. Within the Diagnosis & Treatment segment, Philips offers advanced diagnostic imaging technologies, including magnetic resonance (MRI), computed tomography (CT), X-ray systems, and innovative detector-based spectral CT solutions, alongside molecular and hybrid imaging for nuclear medicine. The company also provides integrated interventional systems and comprehensive echography (ultrasound) solutions, crucial for diagnosis, treatment planning, and guidance in areas like cardiology, general imaging, obstetrics/gynecology, and point-of-care settings. This segment is further supported by proprietary software platforms designed to facilitate diagnostics and interventions, as well as enterprise diagnostic informatics products and related services. The Connected Care division focuses on solutions for critical patient management, emergency response, and sleep and respiratory conditions. Additionally, it delivers electronic medical record (EMR) and broader care management platforms. For Personal Health, Philips provides a range of consumer products, encompassing oral hygiene solutions such as electric toothbrushes, brush heads, and interdental cleaning and teeth whitening systems. This segment also includes infant feeding and digital parenting solutions, along with male grooming and beauty devices. Philips actively pursues strategic collaborations to enhance its offerings, notably partnering with Ibex Medical Analytics Ltd. to jointly promote digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company also maintains a strategic partnership agreement with NICO.LAB. Established in 1891 and headquartered in Amsterdam, the Netherlands, the company adopted its current name, Koninklijke Philips N.V., in May 2013, having previously operated as Koninklijke Philips Electronics N.V.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Koninklijke Philips N.V. (PHIA.AS)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Ossiam EUROPE ESG MACHINE LEARNING | OSX4.DE | 10 | 2.12% |
Funds with Koninklijke Philips among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Koninklijke Philips N.V. operates as a leading global healthcare technology enterprise with a presence across North America and numerous international markets. Its operations are organized into three primary divisions: Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses. Within the Diagnosis & Treatment segment, Philips offers advanced diagnostic imaging technologies, including magnetic resonance (MRI), computed tomography (CT), X-ray systems, and innovative detector-based spectral CT solutions, alongside molecular and hybrid imaging for nuclear medicine. The company also provides integrated interventional systems and comprehensive echography (ultrasound) solutions, crucial for diagnosis, treatment planning, and guidance in areas like cardiology, general imaging, obstetrics/gynecology, and point-of-care settings. This segment is further supported by proprietary software platforms designed to facilitate diagnostics and interventions, as well as enterprise diagnostic informatics products and related services. The Connected Care division focuses on solutions for critical patient management, emergency response, and sleep and respiratory conditions. Additionally, it delivers electronic medical record (EMR) and broader care management platforms. For Personal Health, Philips provides a range of consumer products, encompassing oral hygiene solutions such as electric toothbrushes, brush heads, and interdental cleaning and teeth whitening systems. This segment also includes infant feeding and digital parenting solutions, along with male grooming and beauty devices. Philips actively pursues strategic collaborations to enhance its offerings, notably partnering with Ibex Medical Analytics Ltd. to jointly promote digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company also maintains a strategic partnership agreement with NICO.LAB. Established in 1891 and headquartered in Amsterdam, the Netherlands, the company adopted its current name, Koninklijke Philips N.V., in May 2013, having previously operated as Koninklijke Philips Electronics N.V.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free